Lymphoma Laboratory Workup
A comprehensive lymphoma workup requires complete blood count with differential, lactate dehydrogenase, comprehensive metabolic panel, hepatitis B and C screening, HIV testing, beta-2-microglobulin, uric acid, and bone marrow biopsy (except in Hodgkin lymphoma when PET-CT is performed). 1, 2
Essential Core Laboratory Tests
Complete blood count (CBC) with differential and platelets evaluates for cytopenias, leukocytosis, abnormal lymphocyte populations, and potential bone marrow involvement 1, 2
Serum lactate dehydrogenase (LDH) is the single most important serologic prognostic marker, reflecting tumor burden and cell turnover, and is a critical component of the International Prognostic Index 1, 2
Comprehensive metabolic panel including electrolytes, renal function (creatinine, BUN), and liver function tests (AST, ALT, alkaline phosphatase, bilirubin, albumin) assesses organ function and potential disease involvement 1, 2
Uric acid is essential for assessing tumor lysis syndrome risk, particularly critical before initiating treatment in high tumor burden cases 3, 1, 2
Mandatory Infectious Disease Screening
Hepatitis B testing (HBsAg, anti-HBc, anti-HBs) is required before initiating anti-CD20 monoclonal antibody therapy (rituximab) due to the risk of potentially fatal hepatitis B reactivation 3, 1, 2
Hepatitis C screening is particularly important for high-risk patients and those with splenic marginal zone lymphoma 3, 1, 2
HIV serology is mandatory as HIV status affects prognosis and treatment selection 3, 2
Additional Prognostic Markers
Beta-2-microglobulin is an important prognostic marker, especially in follicular lymphoma where it is incorporated into the revised FLIPI 2 scoring system 3, 1, 2
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are required for Hodgkin lymphoma staging and risk stratification 3
Protein electrophoresis is recommended for B-cell lymphomas to detect monoclonal proteins and evaluate for potential paraproteinemia 1, 2
Bone Marrow Evaluation
Bone marrow aspirate and biopsy are essential for staging in most lymphomas, with involvement occurring in 39% of low-grade, 36% of intermediate-grade, and 18% of high-grade lymphomas 3, 1
Bone marrow biopsy is no longer indicated in Hodgkin lymphoma when PET-CT is performed, as PET-CT has higher sensitivity for detecting bone marrow involvement 3, 4
For non-Hodgkin lymphomas, bone marrow biopsy remains important even with PET-CT imaging 4
Tissue-Based Immunophenotyping
Flow cytometry on peripheral blood or bone marrow is essential for determining lymphoma subtype and clonality 1
The initial immunophenotyping panel should include pan-B cell markers (CD19, CD20, CD22) and pan-T cell markers (CD3, CD5) 1
Tissue specimens require a minimal mandatory antibody panel including CD45, CD20, and CD3 2
Subtype-Specific Testing
Follicular Lymphoma
- Beta-2-microglobulin, diameter of largest lymph node measurement, and hemoglobin level are incorporated into FLIPI 2 prognostic scoring 3
Gastric MALT Lymphoma
- Helicobacter pylori testing by histochemistry or urea breath test is mandatory 3
- FISH analysis or PCR for t(11;18) detection identifies patients unlikely to respond to antibiotic therapy 3
Hodgkin Lymphoma
- ESR is specifically required for risk stratification 3
Pre-Treatment Cardiac and Pulmonary Assessment
Electrocardiography (ECG) and echocardiography or MUGA scan are required before anthracycline-based chemotherapy regimens to assess left ventricular ejection fraction 3, 1
Pulmonary function tests should be performed before treatment initiation, particularly when bleomycin-containing regimens are planned 3
Special Circumstances
Lumbar puncture with cerebrospinal fluid analysis (cell count, flow cytometry, cytology) should be performed in high-risk patients with suspected CNS involvement 1, 2
Tumor lysis syndrome panel (LDH, uric acid, potassium, phosphorus, calcium) is especially important in pediatric patients and those with high tumor burden before initiating treatment 1
Coagulation studies (PT, PTT, fibrinogen) assess for disseminated intravascular coagulation in aggressive lymphomas 1
Critical Pitfalls to Avoid
Fine-needle aspiration is inappropriate for reliable lymphoma diagnosis; excisional or core needle biopsy providing adequate tissue is strongly preferred for accurate diagnosis and immunohistochemistry 3, 2, 5
Hepatitis B reactivation can be fatal during rituximab therapy if not identified and managed prophylactically with antiviral therapy 2
Relying on inadequate tissue samples from core biopsies may miss heterogeneity in follicular lymphoma grading; re-biopsy may be required 3
Bone marrow biopsy must still be performed if PET-CT is not available for staging 3